ID   MPIP1_HUMAN             Reviewed;         524 AA.
AC   P30304; Q8IZH5; Q96IL3; Q9H2F2;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   28-JUN-2023, entry version 210.
DE   RecName: Full=M-phase inducer phosphatase 1;
DE            EC=3.1.3.48;
DE   AltName: Full=Dual specificity phosphatase Cdc25A;
GN   Name=CDC25A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLY-182.
RX   PubMed=1836978; DOI=10.1016/0092-8674(91)90294-9;
RA   Galaktionov K.I., Beach D.;
RT   "Specific activation of cdc25 tyrosine phosphatases by B-type cyclins:
RT   evidence for multiple roles of mitotic cyclins.";
RL   Cell 67:1181-1194(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Varmeh-Ziaie S., Manfredi J.J.;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-88.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 37-234 (ISOFORM 2).
RX   PubMed=11139144; DOI=10.1078/0171-9335-00115;
RA   Wegener S., Hampe W., Herrmann D., Schaller H.C.;
RT   "Alternative splicing in the regulatory region of the human phosphatases
RT   CDC25A and CDC25C.";
RL   Eur. J. Cell Biol. 79:810-815(2000).
RN   [6]
RP   INTERACTION WITH CHEK2, PHOSPHORYLATION AT SER-124 BY CHEK2, AND
RP   MUTAGENESIS OF SER-124.
RX   PubMed=11298456; DOI=10.1038/35071124;
RA   Falck J., Mailand N., Syljuaasen R.G., Bartek J., Lukas J.;
RT   "The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA
RT   synthesis.";
RL   Nature 410:842-847(2001).
RN   [7]
RP   UBIQUITINATION BY THE APC/C UBIQUITIN LIGASE COMPLEX, DOMAIN KEN BOX MOTIF,
RP   AND MUTAGENESIS OF 141-LYS--ASN-143.
RX   PubMed=12234927; DOI=10.1093/emboj/cdf491;
RA   Donzelli M., Squatrito M., Ganoth D., Hershko A., Pagano M., Draetta G.F.;
RT   "Dual mode of degradation of Cdc25 A phosphatase.";
RL   EMBO J. 21:4875-4884(2002).
RN   [8]
RP   PHOSPHORYLATION AT SER-124, AND MUTAGENESIS OF SER-124.
RX   PubMed=12399544; DOI=10.1073/pnas.182557299;
RA   Zhao H., Watkins J.L., Piwnica-Worms H.;
RT   "Disruption of the checkpoint kinase 1/cell division cycle 25A pathway
RT   abrogates ionizing radiation-induced S and G2 checkpoints.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14795-14800(2002).
RN   [9]
RP   PHOSPHORYLATION AT SER-124; SER-178; SER-279 AND SER-293, AND MUTAGENESIS
RP   OF SER-124; SER-178; SER-279 AND SER-293.
RX   PubMed=12676583; DOI=10.1016/s1535-6108(03)00048-5;
RA   Soerensen C.S., Syljuaesen R.G., Falck J., Schroeder T., Roennstrand L.,
RA   Khanna K.K., Zhou B.-B., Bartek J., Lukas J.;
RT   "Chk1 regulates the S phase checkpoint by coupling the physiological
RT   turnover and ionizing radiation-induced accelerated proteolysis of
RT   Cdc25A.";
RL   Cancer Cell 3:247-258(2003).
RN   [10]
RP   INTERACTION WITH BTRC; CUL1 AND FBXW11, PHOSPHODEGRON MOTIF,
RP   PHOSPHORYLATION AT SER-76 AND SER-124, UBIQUITINATION, AND MUTAGENESIS OF
RP   SER-76; SER-79; ASP-81 AND SER-82.
RX   PubMed=14681206; DOI=10.1101/gad.1157503;
RA   Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J., Harper J.W.;
RT   "SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein
RT   phosphatase.";
RL   Genes Dev. 17:3062-3074(2003).
RN   [11]
RP   PHOSPHORYLATION, AND MUTAGENESIS OF CYS-431.
RX   PubMed=12676925; DOI=10.1074/jbc.m300229200;
RA   Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H., Fesik S.,
RA   Zhang H.;
RT   "Chk1 mediates S and G2 arrests through Cdc25A degradation in response to
RT   DNA-damaging agents.";
RL   J. Biol. Chem. 278:21767-21773(2003).
RN   [12]
RP   PHOSPHORYLATION AT SER-76; SER-124 AND SER-178, AND MUTAGENESIS OF SER-76;
RP   SER-124 AND SER-178.
RX   PubMed=12759351; DOI=10.1074/jbc.m302704200;
RA   Hassepass I., Voit R., Hoffmann I.;
RT   "Phosphorylation at serine 75 is required for UV-mediated degradation of
RT   human Cdc25A phosphatase at the S-phase checkpoint.";
RL   J. Biol. Chem. 278:29824-29829(2003).
RN   [13]
RP   INTERACTION WITH CCNB1 AND YWHAE, PHOSPHORYLATION AT SER-178 AND THR-507,
RP   AND MUTAGENESIS OF SER-178; CYS-431; THR-507; LYS-514 AND ARG-520.
RX   PubMed=14559997; DOI=10.1128/mcb.23.21.7488-7497.2003;
RA   Chen M.-S., Ryan C.E., Piwnica-Worms H.;
RT   "Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase
RT   through 14-3-3 binding.";
RL   Mol. Cell. Biol. 23:7488-7497(2003).
RN   [14]
RP   INTERACTION WITH PIM1.
RX   PubMed=16356754; DOI=10.1016/j.biocel.2005.10.010;
RA   Bachmann M., Kosan C., Xing P.X., Montenarh M., Hoffmann I., Moroy T.;
RT   "The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and
RT   activates the G2/M specific phosphatase Cdc25C.";
RL   Int. J. Biochem. Cell Biol. 38:430-443(2006).
RN   [15]
RP   PHOSPHORYLATION AT SER-79; SER-82 AND SER-88.
RX   PubMed=19734889; DOI=10.1038/ncb1969;
RA   Melixetian M., Klein D.K., Soerensen C.S., Helin K.;
RT   "NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint.";
RL   Nat. Cell Biol. 11:1247-1253(2009).
RN   [16]
RP   PHOSPHORYLATION AT SER-82 AND SER-88.
RX   PubMed=20090422; DOI=10.4161/cc.9.3.10513;
RA   Soerensen C.S., Melixetian M., Klein D.K., Helin K.;
RT   "NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling.";
RL   Cell Cycle 9:450-455(2010).
RN   [17]
RP   DEUBIQUITINATION BY USP17L2.
RX   PubMed=20228808; DOI=10.1038/ncb2041;
RA   Pereg Y., Liu B.Y., O'Rourke K.M., Sagolla M., Dey A., Komuves L.,
RA   French D.M., Dixit V.M.;
RT   "Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing
RT   Cdc25A.";
RL   Nat. Cell Biol. 12:400-406(2010).
RN   [18]
RP   PHOSPHORYLATION AT SER-513 AND SER-519 BY PLK3, UBIQUITINATION, AND
RP   MUTAGENESIS OF SER-513 AND SER-519.
RX   PubMed=21376736; DOI=10.1016/j.mrfmmm.2011.02.006;
RA   Myer D.L., Robbins S.B., Yin M., Boivin G.P., Liu Y., Greis K.D.,
RA   Bahassi el M., Stambrook P.J.;
RT   "Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA damage
RT   but is not sufficient to produce tumors.";
RL   Mutat. Res. 714:1-10(2011).
RN   [19]
RP   INTERACTION WITH HSP90AB1.
RX   PubMed=22843495; DOI=10.1093/hmg/dds303;
RA   Giessrigl B., Krieger S., Rosner M., Huttary N., Saiko P., Alami M.,
RA   Messaoudi S., Peyrat J.F., Maciuk A., Gollinger M., Kopf S., Kazlauskas E.,
RA   Mazal P., Szekeres T., Hengstschlaeger M., Matulis D., Jaeger W.,
RA   Krupitza G.;
RT   "Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A
RT   degradation and cell-cycle attenuation in pancreatic carcinoma cells.";
RL   Hum. Mol. Genet. 21:4615-4627(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107 AND SER-321, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 336-496.
RX   PubMed=9604936; DOI=10.1016/s0092-8674(00)81190-3;
RA   Fauman E.B., Cogswell J.P., Lovejoy B., Rocque W.J., Holmes W.,
RA   Montana V.G., Piwnica-Worms H., Rink M.J., Saper M.A.;
RT   "Crystal structure of the catalytic domain of the human cell cycle control
RT   phosphatase, Cdc25A.";
RL   Cell 93:617-625(1998).
CC   -!- FUNCTION: Tyrosine protein phosphatase which functions as a dosage-
CC       dependent inducer of mitotic progression. Directly dephosphorylates
CC       CDK1 and stimulates its kinase activity. Also dephosphorylates CDK2 in
CC       complex with cyclin E, in vitro.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-tyrosyl-[protein] = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620; EC=3.1.3.48;
CC   -!- ACTIVITY REGULATION: Stimulated by B-type cyclins. Stimulated by PIM1-
CC       mediated phosphorylation.
CC   -!- SUBUNIT: Interacts with CCNB1/cyclin B1. Interacts with YWHAE/14-3-3
CC       epsilon when phosphorylated. Interacts with CUL1 specifically when CUL1
CC       is neddylated and active. Interacts with BTRC/BTRCP1 and FBXW11/BTRCP2.
CC       Interactions with CUL1, BTRC and FBXW11 are enhanced upon DNA damage.
CC       Interacts with PIM1. Interacts with CHEK2; mediates CDC25A
CC       phosphorylation and degradation in response to infrared-induced DNA
CC       damages. Interacts with HSP90AB1; prevents heat shock-mediated CDC25A
CC       degradation and contributes to cell cycle progression
CC       (PubMed:22843495). {ECO:0000269|PubMed:11298456,
CC       ECO:0000269|PubMed:14559997, ECO:0000269|PubMed:14681206,
CC       ECO:0000269|PubMed:16356754, ECO:0000269|PubMed:22843495}.
CC   -!- INTERACTION:
CC       P30304; Q9BSU3: NAA11; NbExp=3; IntAct=EBI-747671, EBI-2585120;
CC       P30304; P04049: RAF1; NbExp=4; IntAct=EBI-747671, EBI-365996;
CC       P30304; P31946: YWHAB; NbExp=10; IntAct=EBI-747671, EBI-359815;
CC       P30304; P27348: YWHAQ; NbExp=3; IntAct=EBI-747671, EBI-359854;
CC       P30304; P63104: YWHAZ; NbExp=2; IntAct=EBI-747671, EBI-347088;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=CDC25A1;
CC         IsoId=P30304-1; Sequence=Displayed;
CC       Name=2; Synonyms=CDC25A2;
CC         IsoId=P30304-2; Sequence=VSP_000860;
CC   -!- DOMAIN: The phosphodegron motif mediates interaction with specific F-
CC       box proteins when phosphorylated. Putative phosphorylation sites at
CC       Ser-79 and Ser-82 appear to be essential for this interaction.
CC       {ECO:0000269|PubMed:12234927}.
CC   -!- PTM: Phosphorylated by CHEK1 on Ser-76, Ser-124, Ser-178, Ser-279, Ser-
CC       293 and Thr-507 during checkpoint mediated cell cycle arrest. Also
CC       phosphorylated by CHEK2 on Ser-124, Ser-279, and Ser-293 during
CC       checkpoint mediated cell cycle arrest. Phosphorylation on Ser-178 and
CC       Thr-507 creates binding sites for YWHAE/14-3-3 epsilon which inhibits
CC       CDC25A. Phosphorylation on Ser-76, Ser-124, Ser-178, Ser-279 and Ser-
CC       293 may also promote ubiquitin-dependent proteolysis of CDC25A by the
CC       SCF complex. Phosphorylation of CDC25A at Ser-76 by CHEK1 primes it for
CC       subsequent phosphorylation at Ser-79, Ser-82 and Ser-88 by NEK11.
CC       Phosphorylation by NEK11 is required for BTRC-mediated
CC       polyubiquitination and degradation. Phosphorylation by PIM1 leads to an
CC       increase in phosphatase activity. Phosphorylated by PLK3 following DNA
CC       damage, leading to promote its ubiquitination and degradation.
CC       {ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:12399544,
CC       ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676925,
CC       ECO:0000269|PubMed:12759351, ECO:0000269|PubMed:14559997,
CC       ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:19734889,
CC       ECO:0000269|PubMed:20090422, ECO:0000269|PubMed:20228808,
CC       ECO:0000269|PubMed:21376736}.
CC   -!- PTM: Ubiquitinated by the anaphase promoting complex/cyclosome (APC/C)
CC       ubiquitin ligase complex that contains FZR1/CDH1 during G1 phase
CC       leading to its degradation by the proteasome. Ubiquitinated by a SCF
CC       complex containing BTRC and FBXW11 during S phase leading to its
CC       degradation by the proteasome. Deubiquitination by USP17L2/DUB3 leads
CC       to its stabilization. {ECO:0000269|PubMed:20228808}.
CC   -!- SIMILARITY: Belongs to the MPI phosphatase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/40004/CDC25A";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdc25a/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M81933; AAA58415.1; -; mRNA.
DR   EMBL; AY137580; AAN11305.1; -; mRNA.
DR   EMBL; AF527417; AAM77917.1; -; Genomic_DNA.
DR   EMBL; BC007401; AAH07401.1; -; mRNA.
DR   EMBL; BC018642; AAH18642.1; -; mRNA.
DR   EMBL; AF277722; AAG41884.1; -; mRNA.
DR   CCDS; CCDS2760.1; -. [P30304-1]
DR   CCDS; CCDS2761.1; -. [P30304-2]
DR   PIR; A41648; A41648.
DR   RefSeq; NP_001780.2; NM_001789.2. [P30304-1]
DR   RefSeq; NP_963861.1; NM_201567.1. [P30304-2]
DR   RefSeq; XP_011532618.1; XM_011534316.1.
DR   PDB; 1C25; X-ray; 2.30 A; A=337-496.
DR   PDBsum; 1C25; -.
DR   AlphaFoldDB; P30304; -.
DR   SMR; P30304; -.
DR   BioGRID; 107428; 140.
DR   DIP; DIP-166N; -.
DR   ELM; P30304; -.
DR   IntAct; P30304; 47.
DR   MINT; P30304; -.
DR   STRING; 9606.ENSP00000303706; -.
DR   BindingDB; P30304; -.
DR   ChEMBL; CHEMBL3775; -.
DR   DrugCentral; P30304; -.
DR   DEPOD; CDC25A; -.
DR   GlyCosmos; P30304; 1 site, 1 glycan.
DR   GlyGen; P30304; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P30304; -.
DR   PhosphoSitePlus; P30304; -.
DR   BioMuta; CDC25A; -.
DR   DMDM; 50403734; -.
DR   EPD; P30304; -.
DR   jPOST; P30304; -.
DR   MassIVE; P30304; -.
DR   MaxQB; P30304; -.
DR   PaxDb; P30304; -.
DR   PeptideAtlas; P30304; -.
DR   ProteomicsDB; 54652; -. [P30304-1]
DR   ProteomicsDB; 54653; -. [P30304-2]
DR   Antibodypedia; 1619; 1888 antibodies from 47 providers.
DR   DNASU; 993; -.
DR   Ensembl; ENST00000302506.8; ENSP00000303706.3; ENSG00000164045.12. [P30304-1]
DR   Ensembl; ENST00000351231.7; ENSP00000343166.3; ENSG00000164045.12. [P30304-2]
DR   GeneID; 993; -.
DR   KEGG; hsa:993; -.
DR   MANE-Select; ENST00000302506.8; ENSP00000303706.3; NM_001789.3; NP_001780.2.
DR   UCSC; uc003csh.2; human. [P30304-1]
DR   AGR; HGNC:1725; -.
DR   CTD; 993; -.
DR   DisGeNET; 993; -.
DR   GeneCards; CDC25A; -.
DR   HGNC; HGNC:1725; CDC25A.
DR   HPA; ENSG00000164045; Tissue enhanced (bone marrow, lymphoid tissue, testis).
DR   MIM; 116947; gene.
DR   neXtProt; NX_P30304; -.
DR   OpenTargets; ENSG00000164045; -.
DR   PharmGKB; PA26259; -.
DR   VEuPathDB; HostDB:ENSG00000164045; -.
DR   eggNOG; KOG3772; Eukaryota.
DR   GeneTree; ENSGT00940000160737; -.
DR   HOGENOM; CLU_014464_0_1_1; -.
DR   InParanoid; P30304; -.
DR   OMA; NSAPAQM; -.
DR   OrthoDB; 12481at2759; -.
DR   PhylomeDB; P30304; -.
DR   TreeFam; TF101056; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   PathwayCommons; P30304; -.
DR   Reactome; R-HSA-1362277; Transcription of E2F targets under negative control by DREAM complex.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-176187; Activation of ATR in response to replication stress.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69273; Cyclin A/B1/B2 associated events during G2/M transition.
DR   Reactome; R-HSA-69601; Ubiquitin Mediated Degradation of Phosphorylated Cdc25A.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   SignaLink; P30304; -.
DR   SIGNOR; P30304; -.
DR   BioGRID-ORCS; 993; 65 hits in 1186 CRISPR screens.
DR   ChiTaRS; CDC25A; human.
DR   EvolutionaryTrace; P30304; -.
DR   GeneWiki; CDC25A; -.
DR   GenomeRNAi; 993; -.
DR   Pharos; P30304; Tchem.
DR   PRO; PR:P30304; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P30304; protein.
DR   Bgee; ENSG00000164045; Expressed in secondary oocyte and 134 other tissues.
DR   ExpressionAtlas; P30304; baseline and differential.
DR   Genevisible; P30304; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IBA:GO_Central.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0110032; P:positive regulation of G2/MI transition of meiotic cell cycle; IBA:GO_Central.
DR   GO; GO:0006470; P:protein dephosphorylation; IEA:InterPro.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0009314; P:response to radiation; IDA:UniProtKB.
DR   CDD; cd01530; Cdc25; 1.
DR   Gene3D; 3.40.250.10; Rhodanese-like domain; 1.
DR   InterPro; IPR000751; MPI_Phosphatase.
DR   InterPro; IPR001763; Rhodanese-like_dom.
DR   InterPro; IPR036873; Rhodanese-like_dom_sf.
DR   PANTHER; PTHR10828:SF46; M-PHASE INDUCER PHOSPHATASE 1; 1.
DR   PANTHER; PTHR10828; M-PHASE INDUCER PHOSPHATASE DUAL SPECIFICITY PHOSPHATASE CDC25; 1.
DR   Pfam; PF06617; M-inducer_phosp; 1.
DR   Pfam; PF00581; Rhodanese; 1.
DR   PRINTS; PR00716; MPIPHPHTASE.
DR   SMART; SM00450; RHOD; 1.
DR   SUPFAM; SSF52821; Rhodanese/Cell cycle control phosphatase; 1.
DR   PROSITE; PS50206; RHODANESE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell division; Hydrolase;
KW   Mitosis; Phosphoprotein; Protein phosphatase; Reference proteome;
KW   Ubl conjugation.
FT   CHAIN           1..524
FT                   /note="M-phase inducer phosphatase 1"
FT                   /id="PRO_0000198641"
FT   DOMAIN          376..482
FT                   /note="Rhodanese"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00173"
FT   REGION          264..317
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           74..84
FT                   /note="Phosphodegron"
FT   MOTIF           141..143
FT                   /note="KEN box"
FT   COMPBIAS        274..288
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        431
FT   MOD_RES         76
FT                   /note="Phosphoserine; by CHEK1"
FT                   /evidence="ECO:0000269|PubMed:12759351,
FT                   ECO:0000269|PubMed:14681206"
FT   MOD_RES         79
FT                   /note="Phosphoserine; by NEK11"
FT                   /evidence="ECO:0000269|PubMed:19734889"
FT   MOD_RES         82
FT                   /note="Phosphoserine; by NEK11"
FT                   /evidence="ECO:0000269|PubMed:19734889,
FT                   ECO:0000269|PubMed:20090422"
FT   MOD_RES         88
FT                   /note="Phosphoserine; by NEK11"
FT                   /evidence="ECO:0000269|PubMed:19734889,
FT                   ECO:0000269|PubMed:20090422"
FT   MOD_RES         107
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         124
FT                   /note="Phosphoserine; by CHEK1 and CHEK2"
FT                   /evidence="ECO:0000269|PubMed:11298456,
FT                   ECO:0000269|PubMed:12399544, ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12759351, ECO:0000269|PubMed:14681206"
FT   MOD_RES         178
FT                   /note="Phosphoserine; by CHEK1"
FT                   /evidence="ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12759351, ECO:0000269|PubMed:14559997"
FT   MOD_RES         279
FT                   /note="Phosphoserine; by CHEK1 and CHEK2"
FT                   /evidence="ECO:0000269|PubMed:12676583"
FT   MOD_RES         293
FT                   /note="Phosphoserine; by CHEK1 and CHEK2"
FT                   /evidence="ECO:0000269|PubMed:12676583"
FT   MOD_RES         321
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         507
FT                   /note="Phosphothreonine; by CHEK1"
FT                   /evidence="ECO:0000269|PubMed:14559997"
FT   MOD_RES         513
FT                   /note="Phosphoserine; by PLK3"
FT                   /evidence="ECO:0000269|PubMed:21376736"
FT   MOD_RES         519
FT                   /note="Phosphoserine; by PLK3"
FT                   /evidence="ECO:0000269|PubMed:21376736"
FT   VAR_SEQ         144..183
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11139144, ECO:0000303|Ref.2"
FT                   /id="VSP_000860"
FT   VARIANT         88
FT                   /note="S -> F (in dbSNP:rs3731499)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_020932"
FT   VARIANT         182
FT                   /note="R -> G (in dbSNP:rs6771386)"
FT                   /evidence="ECO:0000269|PubMed:1836978"
FT                   /id="VAR_023532"
FT   VARIANT         182
FT                   /note="R -> W (in dbSNP:rs6771386)"
FT                   /id="VAR_023533"
FT   MUTAGEN         76
FT                   /note="S->A: Abolishes ubiquitination and impairs
FT                   CHEK1-dependent degradation following checkpoint
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:12759351,
FT                   ECO:0000269|PubMed:14681206"
FT   MUTAGEN         79
FT                   /note="S->A: Abrogates interactions with BTRC and FBXW11
FT                   and prevents ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:14681206"
FT   MUTAGEN         81
FT                   /note="D->A: Abrogates interactions with BTRC and FBXW11
FT                   and prevents ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:14681206"
FT   MUTAGEN         82
FT                   /note="S->A: Abrogates interactions with BTRC and FBXW11
FT                   and prevents ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:14681206"
FT   MUTAGEN         124
FT                   /note="S->A: Abrogates phosphorylation by CHEK2 and
FT                   infrared-induced degradation. Increases basal stability and
FT                   impairs CHEK1-dependent degradation following checkpoint
FT                   activation; when associated with A-178; A-279 and A-293."
FT                   /evidence="ECO:0000269|PubMed:11298456,
FT                   ECO:0000269|PubMed:12399544, ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12759351"
FT   MUTAGEN         141..143
FT                   /note="KEN->AAA: Prevents ubiquitination and subsequent
FT                   degradation by the APC/C ubiquitin ligase complex."
FT                   /evidence="ECO:0000269|PubMed:12234927"
FT   MUTAGEN         178
FT                   /note="S->A: Increases basal stability and impairs
FT                   CHEK1-dependent degradation following checkpoint
FT                   activation; when associated with A-124; A-279 and A-293.
FT                   Abrogates 14-3-3 protein binding."
FT                   /evidence="ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12759351, ECO:0000269|PubMed:14559997"
FT   MUTAGEN         279
FT                   /note="S->A: Increases basal stability and impairs
FT                   CHEK1-dependent degradation following checkpoint
FT                   activation; when associated with A-124; A-178 and A-293."
FT                   /evidence="ECO:0000269|PubMed:12676583"
FT   MUTAGEN         293
FT                   /note="S->A: Increases basal stability and impairs
FT                   CHEK1-dependent degradation following checkpoint
FT                   activation; when associated with A-124; A-178 and A-279."
FT                   /evidence="ECO:0000269|PubMed:12676583"
FT   MUTAGEN         431
FT                   /note="C->S: Abolishes phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:12676925,
FT                   ECO:0000269|PubMed:14559997"
FT   MUTAGEN         507
FT                   /note="T->A: Abrogates 14-3-3 protein binding; increases
FT                   binding to cyclin B1."
FT                   /evidence="ECO:0000269|PubMed:14559997"
FT   MUTAGEN         513
FT                   /note="S->A: Increased stability following IR treatment."
FT                   /evidence="ECO:0000269|PubMed:21376736"
FT   MUTAGEN         513
FT                   /note="S->D: Mimicks phosphorylation state, leading to
FT                   promote degradation following IR treatment."
FT                   /evidence="ECO:0000269|PubMed:21376736"
FT   MUTAGEN         514
FT                   /note="K->L: Abrogates binding to CCNB1; when associated
FT                   with L-520."
FT                   /evidence="ECO:0000269|PubMed:14559997"
FT   MUTAGEN         519
FT                   /note="S->A: Increased stability following IR treatment."
FT                   /evidence="ECO:0000269|PubMed:21376736"
FT   MUTAGEN         519
FT                   /note="S->D: Mimicks phosphorylation state, leading to
FT                   promote degradation following IR treatment."
FT                   /evidence="ECO:0000269|PubMed:21376736"
FT   MUTAGEN         520
FT                   /note="R->L: Abrogates binding to CCNB1; when associated
FT                   with L-514."
FT                   /evidence="ECO:0000269|PubMed:14559997"
FT   CONFLICT        6..10
FT                   /note="EPPHR -> SPAP (in Ref. 1; AAA58415)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        180..181
FT                   /note="PA -> QL (in Ref. 1; AAA58415)"
FT                   /evidence="ECO:0000305"
FT   STRAND          341..344
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   HELIX           362..369
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   TURN            370..376
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   STRAND          377..384
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   HELIX           388..392
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   HELIX           405..411
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   TURN            412..414
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   STRAND          423..430
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   STRAND          432..436
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   HELIX           437..451
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   STRAND          463..466
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   HELIX           469..477
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   HELIX           478..480
FT                   /evidence="ECO:0007829|PDB:1C25"
FT   STRAND          481..484
FT                   /evidence="ECO:0007829|PDB:1C25"
SQ   SEQUENCE   524 AA;  59087 MW;  B2F6B792D4E6122B CRC64;
     MELGPEPPHR RRLLFACSPP PASQPVVKAL FGASAAGGLS PVTNLTVTMD QLQGLGSDYE
     QPLEVKNNSN LQRMGSSEST DSGFCLDSPG PLDSKENLEN PMRRIHSLPQ KLLGCSPALK
     RSHSDSLDHD IFQLIDPDEN KENEAFEFKK PVRPVSRGCL HSHGLQEGKD LFTQRQNSAP
     ARMLSSNERD SSEPGNFIPL FTPQSPVTAT LSDEDDGFVD LLDGENLKNE EETPSCMASL
     WTAPLVMRTT NLDNRCKLFD SPSLCSSSTR SVLKRPERSQ EESPPGSTKR RKSMSGASPK
     ESTNPEKAHE TLHQSLSLAS SPKGTIENIL DNDPRDLIGD FSKGYLFHTV AGKHQDLKYI
     SPEIMASVLN GKFANLIKEF VIIDCRYPYE YEGGHIKGAV NLHMEEEVED FLLKKPIVPT
     DGKRVIVVFH CEFSSERGPR MCRYVRERDR LGNEYPKLHY PELYVLKGGY KEFFMKCQSY
     CEPPSYRPMH HEDFKEDLKK FRTKSRTWAG EKSKREMYSR LKKL
//
